key: cord-0828750-tc892moq
authors: Li, Chang; Wang, Lin; Ren, Linzhu
title: Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection
date: 2020-06-24
journal: Virus Res
DOI: 10.1016/j.virusres.2020.198073
sha: 15dba867591d7e7615fe63ab5971a2a462eed249
doc_id: 828750
cord_uid: tc892moq

The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic. Up to now, numerous medicines have been applied or approved for the prevention and control of the virus infection. However, the efficiency of each medicine or combination is completely different or still unknown. In this review, we discuss the types, characteristics, antiviral mechanisms, and shortcomings of recommended candidate medicines for SARS-CoV-2 infection, as well as perspectives of the drugs for the disease treatment, which may provide a theoretical basis for drug screening and application.

cleaved into at least 16 predicted nonstructural proteins (nsp), among which nsp3, nsp5, nsp12, and nsp13 encode putative papain-like viral protease (PLVP), 3C-like protease (chymotrypsin-like or 3C-like protease, 3CL pro ), RNA-dependent RNA polymerase (RdRp), and helicase, respectively . Besides, the viral ORF1ab, ORF10, and ORF3a proteins can attack heme on hemoglobin 1-β chain synergistically, resulting in decomposing iron to form porphyrin, which will subsequently lead to less and less hemoglobin carrying oxygen and carbon dioxide, produce extremely strong poisoning and inflammation in lung cells, and interfere with the normal heme anabolism pathway . Therefore, S protein and proteins derived from the ORF1ab as well as their cellular receptors, such as ACE2 (Zhou et al., 2020b) , AGTR2 (angiotensin II receptor type 2) , TMPRSS2 (Hoffmann et al., 2020) , and CD147 (Basigin or EMMPRIN) , are the most favorable cellular targets for the development of antiviral compounds.

Since the disease newly emerges, there is no clinically approved antiviral therapy or vaccines for the disease. Hopefully, the virus has highly relationship with bat coronavirus isolate RaTG13 (GenBank No.: MN996532) base on the full-length genome (Jiang and Shi, 2020; Li et al., 2020a; Zhou et al., 2020b) . Thus, many experts and clinicians suggest using anti-coronavirus drugs to prevent and control the disease. Up to now, numerous medicines have been registered or approved for clinical trials for COVID-19 treatment (https://clinicaltrials.gov/ and http://www.chictr.org.cn/). However, the efficiency of each medicine or combination is quite different or still unknown. In this review, we discuss the types, characteristics, antiviral mechanisms, and shortcomings of several recommended candidate medicines for SARS-CoV-2 infection, as well as perspectives of the drugs for the disease treatment. The mechanisms discussed in this article may provide a theoretical basis for drug screening and application.

Repurposed drugs have emerged as attractive sources for the prevention and treatment of the SARS-CoV-2 infection, which could shorten the time and reduce the cost compared to de novo drug screen (Baron et al., 2020; Chen et al., 2020c; Liu et al., 2020d; Omar, 2020; Sohini and Narayanaswamy, 2020; Xu et al., 2020a; Zhou et al., 2020c) . For example, the antiviral medicines ledipasvir or velpatasvir are particularly attractive candidates to treat COVID-19 with minimal side effects . As reported by Chen and colleagues, Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be attractive drugs that can inhibit 3C-like protease of the virus . Zhou et al. identified three potential drug combinations (sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene combined with emodin) targeting SARS-CoV-2 by network-based methodologies . Sohini et al. found 20 known candidates, including some synthetic molecules and phytochemicals, which might exhibit antiviral activities by binding to the main protease of SARS-CoV-2 (Sohini and Narayanaswamy, 2020) . Among the repurposed drugs (Table 1) , remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and ribavirin are promising candidates in the development of the antiviral drugs for SARS-CoV-2 infection, which have shown efficacy to inhibit the coronavirus in vitro or in animal models (Belhadi et al., 2020; Chen et al., 2020c; Guo et al., 2020; Martinez, 2020; Xu et al., 2020a) . Furthermore, according to the 7 th edition of the Guideline recommended by the Prevention, Diagnosis, and Treatment of Novel Coronavirusinduced Pneumonia issued by the National Health Commission (NHC) of the People' Republic of China for the treatment of COVID-19, interferon α (IFN-α), lopinavir/ritonavir, ribavirin, chloroquine phosphate, and arbidol are priority recommendation (PRC, 2020). A recent survey showed that the main antiviral drugs are IFN-α (69.5 %), lopinavir/ritonavir (65.0 %), arbidol (60.0 %), and ribavirin (55.7 %) in China (Liu et al., 2020c) .

Based on the target of the antiviral medicine, there are mainly two types of antiviral compounds recommended in the treatment of the COVID-19. The first type is targeting host J o u r n a l P r e -p r o o f more effective than CQ at inhibiting SARS-CoV-2 in vitro and in vivo (Gautret et al., 2020; Liu et al., 2020b; Yao et al., 2020b; Zhou et al., 2020a) . Therefore, it was recommended to use 400 mg of hydroxychloroquine sulfate twice daily for 1 day, followed by 200 mg twice daily for 4 more days for the treatment . Furthermore, a combination of hydroxychloroquine sulfate (200 mg, three times per day during ten days) and azithromycin (500 mg on day1 followed by 250 mg per day, the next four days) can significantly reduce the viral load compared with that of the hydroxychloroquine treatment alone (Gautret et al., 2020) . Taken together, the CQ and its derivatives can shorten the course of SARS-CoV-2, reduce the inflammatory responses to infection, inhibit the deterioration of pneumonia, improve lung imaging performance, and promote the negative conversion of the virus (Kearney, 2020; . However, recent reports show that treatment with HCQ is associated with numerous adverse effects in patients with COVID-19, such as frequent QTc prolongation, erythema multiforme, acute generalized exanthematous pustulosis (Bessiere et al., 2020; Delaleu et al., 2020; Mercuro et al., 2020; Monte Serrano et al., 2020; Ren et al., 2020b; Torjesen, 2020) . On Jun 16, 2020, the US Food and Drug Administration revoked the emergency use authorization for chloroquine and hydroxychloroquine due to their lack of efficacy and safety concerns (http://www.chinadaily.com.cn/). Therefore, the safety assessment of CQ/HCQ and the combination of HCQ and other medicine should be conducted for patients with COVID-19.

Arbidol (ARB, also known as umifenovir) is a broad-spectrum antiviral drug that can inhibit numerous DNA and RNA viruses, including influenza virus, Zika virus, West Nile virus and hepatitis C virus (Blaising et al., 2014; Haviernik et al., 2018) . It was reported that ARB can interact with both cellular membranes and viral and/or cellular proteins, and thus preventing membrane fusion, blocking trimerization of the spike glycoprotein and virus infection (Blaising et al., 2014; Vankadari, 2020) . ARB also has immunostimulating effects, such as stimulating the production of interferon, activating the humoral and cellular immune J o u r n a l P r e -p r o o f defense of the body, enhancing the phagocytic activity of macrophages (Blaising et al., 2014; Haviernik et al., 2018) . Moreover, ARB exhibits a prolonged antioxidant capacity by reacting with free radicals in two stages (Proskurnina et al., 2020) . Therefore, it was supposed that ARB can inhibit SARS-CoV-2 infection at several stages, which is currently used in several clinical trials for the COVID-19 treatment. Furthermore, it was reported that ARB combined with Lopinavir/Ritonavir (LPV/r) is better than LPV/r alone in the treatment of the COVID-19 . ARB/IFN-α2b Therapy and ARB/adjuvant therapy are helpful to relieve COVID-19 pneumonia Xu et al., 2020b) . However, another group found that arbidol monotherapy has little effect on improving clinical outcomes of mild/moderate patients (Li et al., 2020d) . These results demonstrate that a combination of different compounds with ARB targeting different stages of the viral infection might be a promising stream in the antiviral treatment of the COVID-19. Notably, it is not recommended to use three or more antiviral drugs simultaneously (PRC, 2020).

Apart from CQ and ARB recommended by WHO and NHC of China, some compounds also exhibit promising characteristics in the treatment of the COVID-19. The first one is teicoplanin, which is a commonly used glycopeptide antibiotic in the treatment of Gram-positive bacterial infection, especially in staphylococcal and streptococcus infections (Baron et al., 2020; Ren et al., 2020c) . Recently, it was reported that the antibiotic can be used against various viruses such as Ebola, influenza virus, flavivirus, hepatitis C virus, HIV, Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV (Colson and Raoult, 2016; Zhou et al., 2016) . Teicoplanin can inhibit entry of the pseudoviruses (HIVluc/2019-nCoV-S) by specifically blocking the activity of host cysteine proteases cathepsin L in the late endosomes, and thus inhibiting the release of genomic viral RNA and the virus replication cycle (Baron et al., 2020; Ren et al., 2020c) . Therefore, the half-maximal (50 %) inhibitory concentration (IC50) of teicoplanin is 1.66 uM on the pseudoviruses, and the J o u r n a l P r e -p r o o f recommended usage is 400-1200 mg/day intravenously or orally (Baron et al., 2020; Ren et al., 2020c ) (Ceccarelli et al., 2020) .

Another compound is niclosamide, which is an FDA-approved anthelminthic drug against tapeworm infections for several decades . It is a multifunctional drug that can inhibit oxidative phosphorylation and stimulate adenosine triphosphatase activity in the mitochondria, regulate multiple signaling pathways and biological processes, including Wnt/β-catenin, mTORC1, STAT3, NF-κB, Notch, NS2B-NS3 interaction, and pH (Kratky and Vinsova, 2011; Pindiprolu and Pindiprolu, 2020; Xu et al., 2020a) . These results suggest that niclosamide has broad-spectrum antiviral activities. Furthermore, the derivatives of niclosamide, such as 2-chloro-4-nitroanilide, O-alkylamino-tethered, or salicylamide derivatives, also exhibit more potent and orally bioavailable for antiviral treatments (Kratky and Vinsova, 2011; Xu et al., 2020a) . Moreover, niclosamide may inhibit endocytosis of SARS-CoV-2 by blocking ACE2, and prevent autophagy of SARS-CoV-2 by inhibiting of S-Phase kinase-associated protein 2 (Pindiprolu and Pindiprolu, 2020) . However, the antiviral activities of niclosamide and its derivatives in SARS-CoV-2 infection need further research and clinical verification.

The first type of highly recommended medicines direct targeting SARS-CoV-2 in clinical trials is repurposed drugs, which interact with viral proteins, especially viral major proteases.

Lopinavir/Ritonavir (also named as Kaletra or Lopimune, LPV/r) is a fixed-dose combination that is currently used to treat HIV infection. Lopinavir is an inhibitor of HIV protease, which prevents cleavage of the viral Gag-Pol polyprotein and results in the J o u r n a l P r e -p r o o f production of immature, non-infectious viral particles (Cao et al., 2020a; Lin et al., 2020b; Liu et al., 2020a; Liu and Wang, 2020; Wang et al., 2020d; Xu et al., 2020a) . Ritonavir works as an inhibitor of cytochrome P450 (CYP450) enzymes, an inhibitor of P glycoprotein, and a glucuronidase inducer, which can inhibit the CYP3A (CYP450, family 3, subfamily A)mediated metabolism of lopinavir, thereby increasing the plasma levels of lopinavir (Cao et al., 2020a; Sevrioukova and Poulos, 2014) . Belhadi et al. reported that LPV/r was associated with the highest total number (2606) in the clinical trials for the COVID-19 treatment (Belhadi et al., 2020) , suggesting the combination is promising in the antiviral therapy of the disease.

An evaluation based on molecular modeling showed that both ritonavir and lopinavir can suitably bind to the endopeptidase C30 (EP_C30) of SARS-CoV-2 and induce significant conformation changes of CEP_C30, with a stronger efficacy induced by ritonavir . However, some groups showed that there was no significant difference between LPV/r group and the standard care group, and LPV/r might results in more adverse events compared with that of the control group (Cao et al., 2020a; Li et al., 2020d) . Therefore, the effectiveness and safety of these drugs need further evaluation.

Additionally, many repurposing drugs targeting viral main proteins were recently evaluated using computer-aided protocols, such as molecular docking Liu et al., 2020d; Omar, 2020; Sohini and Narayanaswamy, 2020) . As reported by Omar, the binding energy of aliskiren, dipyridamole, mopidamol and rosuvastatin to COVID-19 main protease (3CL pro ) is relatively high (Omar, 2020) . Atazanavir has a potential to bind to the viral RdRp (Kd 21.83 nM), helicase (Kd 25.92 nM), 3′-to-5′ exonuclease (Kd 82.36 nM), 2′-Oribose methyltransferase (Kd of 390.67 nM), and endoRNAse (Kd 50.32 nM) (Beck et al., 2020) , suggesting the drug can be used for COVID-19 treatment by inhibiting simultaneous all the subunits of the SARS-CoV-2 replication complex. Dai and colleagues synthesized two compounds (11a and 11b) targeting SARS-CoV-2 M pro and found that these compounds showed good pharmacokinetic properties in vivo with low toxicity (Dai et al., 2020) .

However, whether these drugs or compounds have antiviral effects against SARS-CoV-2 infection still needs clinical evaluation.

The second type of highly recommended drugs targeting the virus is nucleoside analogs, which can disturb or halt the replication of the virus genome.

Remdesivir (GS-5734, RDV) is an adenosine analog originally designed for clinical trials against Ebola virus infections (Amirian and Levy, 2020; Martinez, 2020) . As reported, remdesivir exhibit antiviral activity against multiple viruses, including Marburg virus, Nipah virus, Hendra virus, measles and mumps, respiratory syncytial virus, as well as human and zoonotic coronaviruses, such as HCoV-NL63, HCoVOC43, HCoV-229ESARS-CoV and MERS-CoV in vitro and in non-human primate models Martinez, 2020) , suggesting it has broad-spectrum antiviral activities. It was reported that remdesivir has obvious clinical benefits in rhesus macaques at the early stage of SARS-CoV-2 infection, supporting the early treatment of remdesivir in patients with COVID-19 to prevent the progression of severe pneumonia (Williamson et al., 2020) . The active form of remdesivir in peripheral blood mononuclear cells (PBMCs) can obscure viral RdRp and evade proofreading by viral exonuclease, resulting in a decrease in viral RNA production (Al-Tawfiq et al., 2020; Gao et al., 2020b; Ko et al., 2020; Zhang and Zhou, 2020) . Further studies showed that the active form of remdesivir, CHEMBL2016761 and GS-441524, can bind to the viral RdRp binding pocket and replace natural counterpart ATP, causing insertion of remdesivir as well as three additional nucleotides in the extended viral strand Gordon et al., 2020; Wang et al., 2020d) , and thus resulting in a disturbing viral genome. The relative binding free energy of remdesivir to the RdRp is -8.28±0.65 kcal/mol, which is significantly stronger than that of the natural substrate ATP .

However, in the past few months, remdesivir has been the most controversial drug in the treatment of COVID-19 due to its potential risks on kidney and liver functions (Adamsick et al., 2020; Davies et al., 2020) . Moreover, Remdesivir can only reduce the hospitalization time of patients and has little effect on reducing the mortality rate. Several randomized controlled trials are currently ongoing worldwide to assess the safety and efficacy of this medicine in the treatment of COVID-19.

Favipiravir is a modified pyrazine analog, which acts as a prodrug and undergoes ribosylation and phosphorylation in cells by host enzymes to become active ribofuranosyl triphosphate derivative favipiravir-RTP (Delang et al., 2018; Du and Chen; Furuta et al., 2017) .

Favipiravir-RTP can bind to and inhibit the viral RdRp activity, and thus prevent viral transcription and replication Delang et al., 2018; Furuta et al., 2017) .

Further studies showed that favipiravir-RTP incorporates into a nascent RNA strand, leading to a termination of RNA strand elongation and viral proliferation (Furuta et al., 2017) .

Favipiravir-RTP also acts as a competitor of purine nucleoside binding to the RdRp (Furuta et al., 2017) . These results indicate the compound is a promising antiviral drug targeting a broad range of RNA viruses. Recently, it was reported that favipiravir can inhibit the binding of the E and ORF7a proteins of SARS-CoV-2 to porphyrin, prevent the virus from entering host cells and capture free porphyrin . Results from a clinical trial showed favipiravir has a higher clinical recovery rate and a more effectively reduced incidence of fever, cough than ARB for COVID-19 . Although favipiravir may cause side effects, such as raised serum uric acid, this effect will soon disappear after drug withdrawal . It is worth noting that favipiravir has a teratogenic effect, and therefore cannot be used for pregnant women (Delang et al., 2018; Furuta et al., 2017) .

Ribavirin is a well-known nucleoside analogue that can inhibit a broad-spectrum of viruses. Results of molecular docking show that ribavirin can bind to SARS-CoV-2 RdRp with J o u r n a l P r e -p r o o f a binding energy of -7.8 kcal/mol, forming 13 hydrogen bonds between the RdRp and ribavirin, resulting in the termination of virus replication (Elfiky, 2020) . However, ribavirin monotherapy is ineffective for SARS-CoV-2, but it can cause drug-related side effects including gastrointestinal symptoms, anemia, and liver function changes Rios et al., 2020) . Due to the combination of ribavirin and IFN is effective in treating MERS, combinations of ribavirin and IFN, and ribavirin and LPV/r are still recommended by the latest edition of the Guideline issued by the NHC, PRC PRC, 2020) . Hung et al. evaluated a combination of IFN β-1b, LPV/r, and ribavirin for treating patients with COVID-19, and found that triple antiviral therapy using this combination is safe for mild to moderate COVID-19 patients and is superior to LPV/r alone in relieving symptoms, shortening virus shedding and hospitalization time (Hung et al.) . These results suggest that a combination of different drugs is feasible in the treatment of COVID-19.

Moreover, other nucleoside analogues, such as IDX-184, Sofosbuvir, and β-D-N4hydroxycytidine (NHC, EIDD-1931) appear to be promising inhibitors against SARS-CoV-2 (Elfiky, 2020; Sheahan et al., 2020) . IDX-184 and Sofosbuvir can bind to the virus RdRp with binding energies of -9.0 and -7.5 kcal/mol, and the numbers of hydrogen bonds are 11 and 7, respectively (Elfiky, 2020) . EIDD-1931 produces lethal mutations in the viral genome by increasing the frequency of viral RNA mutations, thus exhibiting a broad-spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and Bat-CoVs (Sheahan et al., 2020) .

Traditional Chinese medicines (TCM) are widely used in China and some Chinese communities outside China, with characteristics of low cost, good curative effect, short duration of treatment, and multiple targets. Numerous facts prove that it is feasible to treat human and animal diseases with TCM, which can effectively relieve symptoms, reduce the development from mild to moderate or severe, improve the cure rate, reduce mortality rate, J o u r n a l P r e -p r o o f and promote the recovery of patient by means of "multi-component, multi-target, multipathway" (Cantwell, 2010; Huang et al., 2020; Luo et al., 2020; Tong et al., 2020; Yuan et al., 2016) .

During the last months, TCMs are widely used in clinical treatments against SARS-CoV-2 infection in China. As a result, TCMs play important roles and have become a highlight of the prevention and control of the COVID-19 (Ang et al., 2020; Ren et al., 2020a; Xu and Zhang, 2020) . It was reported that more than 74,187 (91.5 %) of the confirmed cases of the COVID-19 patients in China were treated with TCMs, 61,449 (90.6 %) of which were used in Hubei Province. Clinical observation shows that the total effective rate of TCMs has reached more than 90 % (http://paper.people.com.cn/rmrb, 2020-03-24) (PRC, 2020), indicating the TCMs is effective in the treatment of the COVID-19.

Generally, different therapeutic logic of TCM is used based on the patient's physical condition and different symptoms, as well as the living environmental conditions. During the last six months, numerous prescriptions against COVID-19 were recommended by NHC based on the different symptoms and different patients Liu et al., 2020c; Tong et al., 2020) . For details dosage, please refer to the latest edition of the guideline issued by the NHC of China PRC, 2020; Xu and Zhang, 2020) . Among these TCMs, the "three drugs, three recipes" with obvious therapeutic effects, such as Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Xuebijing Injection, Qingfei Paidu Decoction, Huashi Baidu Recipe, and Xuanfei Baidu Recipe, have been screened out and highly recommended to treat SARS-CoV-2 infection (http://paper.people.com.cn/rmrb) (Table 2) (PRC, 2020). For details, please read the review articles by Tong et al. and Huang et al. .

For medical observation of COVID-19, several prescriptions can be used clinically, including Huoxiang Zhengqi capsules (pills, liquid, or oral solution), Jinhua Qinggan granules/capsules, Lianhua Qingwen capsules/granules, Shufeng Jiedu capsules/granules, Fangfeng Tongsheng pills/granules, and Yupingfeng San Liu et al., 2020e; PRC, 2020; Xu and Zhang, 2020) .

Huoxiang Zhengqi capsules (pills, liquid, or oral solution, HXZQ) consists of 10 Chinese herbs, with 778-2347 chemical ingredients . Among these ingredients, more than 13 ingredients, including protocatechuic acid, chlorogenic acid, caffeic acid, liquiritin, hesperidin, apigetrin, rosmarinic acid, oxypeucedanin hydrate, byakangelicin, apigenin, glycyrrhizin, nobiletin, and 6-gingerol, are recognized as critical chemical marker compounds (Kim et al., 2014) . HXZQ is widely used to dissipate cold and eliminate dampness targeting on the clinical features of fatigue and gastrointestinal discomfort PRC, 2020) . Moreover, this prescription is also used in the treatment of clinical symptoms as hypodynamia accompanied by gastrointestinal upset, as well as the exterior syndrome of cold-dampness PRC, 2020) . It was reported that HXZQ can regulate the immune response of CD4 + and CD8 + cells and suppress the levels of TNF-α in the intestine (He et al., 2006; Tong et al., 2020) . Results of molecular docking showed that PTGS2, HSP90AB1, CAMSAP2, mPGES-1, LTA4H, NOS2 are possible targets of HXZQ in COVID-19 Tong et al., 2020) . Therefore, HXZQ has anti-inflammatory and immunomodulatory effects in COVID-19 by inhibiting inflammatory factors and regulating immune response Tong et al., 2020) .

Tongsheng pills/granules, Jinhua Qinggan granules/capsules, and Yupingfeng San are commonly used to against influenza virus infection PRC, 2020; Xu and Zhang, 2020) . For example, Lianhua Qingwen capsules/granules (LHQW) composed of 13 herbs, with 733-3084 chemical ingredients , has broad-spectrum activities against J o u r n a l P r e -p r o o f influenza viruses (IAV) (Ding et al., 2017) as well as other respiratory diseases, such as chronic rhinosinusitis (Lin et al., 2020a) , chronic obstructive pulmonary disease (Dong et al., 2014) , etc. LHQW can block the early stage of virus infection, impair the nuclear export of the viral RNP, and modulate immune responses during virus infection (Ding et al., 2017) . LHQW also can inhibit the replication of SARS -CoV-2, affect virus morphology, improve human immunity, and decrease inflammatory response or even cytokine storm Li et al., 2020c; Tong et al., 2020; Ye et al., 2020) . Meanwhile, three components of LHQW, Rutin, Forsythoside E, and Hyperoside, can bind the protease of SARS-CoV-2, with the binding energy of -9.1, -9.0 and -8.7 kcal/mol, respectively, forming hydrogen bonds and hydrophobic interactions between the active components and the viral protease . Moreover, chemical components of LHQW may also target cellular JAK-STAT, EGFR, ACE2, MAPK, PI3K-AKT, and NF-κB, etc Tong et al., 2020) . These results demonstrate that LHQW seems an effective TCM against SARS-CoV-2 infection.

Shufeng Jiedu Capsule/Granule (SFJD), consisting of eight medicinal herbs, is a widely used TCM for its antiviral, antibacterial, antitumor, and anti-inflammatory activities (Mei et al., 2020) . It was reported that SFJD may protect lung injury and neuronal loss by enhancing autophagy and reducing apoptosis in rats with allergic rhinitis (Mei et al., 2020) . It improves upper respiratory tract infection induced by Pseudomonas aeruginosa through various targets, especially ERK phosphorylation . SFJD effectively regulates anti-inflammatory and immunoregulatory activities during acute lung injury through AKT1 regulation (Tao et al., 2017) . Besides, SFJD combined with oseltamivir treatment significantly reduced IAVinduced airway inflammation and pulmonary virus titer . These results suggest SFJD may prevent and cure diseases, especially infectious diseases, by regulating various signal pathways.

Yinqiao san were suggested to use in clinical PRC, 2020; Xu and Zhang, 2020) .

Additionally, QFPD, Huashi Baidu Recipe, and Xuanfei Baidu Recipe are three new prescriptions specifically designed for the COVID-19, which exhibit active and effective roles in the prevention and treatment of the disease.

QFPD has more than 300 active ingredients and can act on more than 790 targets.

QFPD might inhibit the invasion and replication of SARS-CoV-2 by directly targeting the viral 3C protein and host ACE2 . Recent studies showed that QFPD can improve several pathways in patients with COVID-19, such as response to oxygen levels, response to oxidative stress, and blood circulation . Moreover, QFPD also can inhibit arachidonic acid metabolic pathway, and thereby regulating inflammatory cytokines (Ren et al., 2020c) , suggesting this decoction has a positive effect on COVID-19 treatment. However, the exact biological mechanisms and side effects of these prescriptions need to be further evaluated.

Moreover, Xuanfei Baidu Recipe (XFBD) consists of 13 herbs, which acts on lung meridian by balancing immunity, eliminating inflammation, regulating hepatic and biliary metabolism, and recovering energy metabolism balance (Wang et al., 2020f) .

For severe and critical infection of SARS-CoV-2, Xuebijing Injection, Maxing Shigan tang, and Baihe Gujin tang can be used in clinically PRC, 2020; Xu and Zhang, 2020) . Xuebijing Injection derived from 5 herbs is suitable for systemic inflammatory response syndrome induced by infection and multiple organ dysfunction syndromes (Government; Jin et al., 2020; PRC, 2020; Tong et al., 2020) . It was reported that the injection has the potential immunoregulatory ability, antibacterial, anti-endotoxin effects (Gao et al., 2013) , as well as an anti-inflammatory effect by inhibiting the release of serum pro-inflammatory cytokines (Shen J o u r n a l P r e -p r o o f et al., 2013). Therefore, for severe and critical patients of the COVID-19, Xuebijing Injection is recommended for clearing heat, detoxicating, and blood-quickening PRC, 2020) .

Interferon and glucocorticoid are also used in the treatment of the COVID-19.

Interferons are well-known agents with broad-spectrum antiviral activities. Recent studies have shown that SARS-CoV-2 is sensitive to type I interferon pretreatment in vitro (Lokugamage et al., 2020) . During the SARS-CoV-2 infection, phosphorylation of signal transducers and activators of transcription 1 (STAT1) and levels of IFN stimulated gene (ISG) proteins were significantly induced in the IFN-pretreated cells compared with that of the control cells and the cells infected with SARS-CoV but without IFN pretreatment (Lokugamage et al., 2020) . Therefore, as recommended by NHC, China, IFN-α is used by atomization inhalation, with 5 million U or equivalent dose each time, 2 times/day for no more than 10 days (Dong et al., 2020; PRC, 2020) . Besides, IFN combined with other antiviral compounds is also suggested for the treatment of the COVID-19, such as LPV/r combined with IFN-β, ribavirin plus IFN PRC, 2020) .

Additionally, glucocorticoids can exhibit anti-inflammatory activity by inhibiting gene transcription or immune response. It was reported that corticosteroid dexamethasone may reduce the mortality of severe COVID-19 patients by about one-third via limiting proinflammatory cytokines (Ledford, 2020; Theoharides and Conti, 2020) . However, glucocorticoid-induced side effects are complex and frequent, such as inhibiting the protective function of T cells and B cells, blocking the clearance function of macrophages, etc. (Schacke et al., 2002; Theoharides and Conti, 2020) . Therefore, glucocorticoid is suggested for a short period with 1-2 mg/kg/d for 3-5 days Jin et al., 2020; PRC, 2020) .

Notably, the side effects caused by interferon and glucocorticoid cannot be ignored.

Therefore, only appropriate use of interferon and glucocorticoids are recommended, which can significantly improve the clinical symptoms of patients with SARS-CoV-2, reduce disease progression, and accelerate the absorption of lung lesions Jin et al., 2020; PRC, 2020) .

In conclusion, SARS-CoV-2 is a highly infectious and pathogenic virus. It can be transmitted through contact and air, and may also be transmitted via mother-to-fetus and fecal-oral transmission routes. Although a variety of candidate medicines have been applied in clinical trials, the efficacy of these drugs still needs further research, especially in doubleblinded, randomized, placebo-controlled trials.

It is worth noting that SARS-CoV-2 is an RNA virus that is easy to mutate, and some variations in the population were reported in recent studies, which may substantially affect its pathogenicity Wang et al., 2020a; Yao et al., 2020a; Zhao et al., 2020) .

Drugs against the viral proteins may be ineffective as viral genes continue to mutate, while drugs targeting cellular proteins may have better application prospects. Therefore, it is still one of the most important tasks to screen efficient and safe drugs according to the conserved sequences of the virus or the characteristics of host proteins. Besides, since candidate drugs and therapies are still being screened or in clinical trials, the combination of traditional Chinese medicine and other antiviral drugs as the first choice for the treatment of the disease can achieve better therapeutic effects. For critical patients, reasonable use of drugs should be combined with the actual situation of patients. Moreover, the adverse effects of each drug or therapy need further evaluation and follow-up.

The author declares no conflict of interest. All authors have approved the final version of the manuscript.

Conceptualization, RLZ; writing-original draft preparation, RLZ and LC; writing revision, WL and RLZ; supervision, RLZ; and funding acquisition, RLZ and LC. All authors critically read and contributed to the manuscript, approving its final version. Tables   Table 1 Possible 

Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Remdesivir as a possible therapeutic option for the COVID-19

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health 9

Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines

Teicoplanin: an alternative drug for the treatment of COVID-19?

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drugtarget interaction deep learning model

A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Arbidol as a broad-spectrum antiviral: an update

Traditional Chinese veterinary medicine: the mechanism and management of acupuncture for chronic pain

Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Intensive Care

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a J o u r n a l P r e -p r o o f patient with atypical pneumonia after visiting Wuhan

Repositioning Chloroquine as Ideal Antiviral Prophylactic against COVID-19 -Time is Now

Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv

A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Fighting viruses with antibiotics: an overlooked path

AGTR2, One Possible Novel Key Gene for the Entry of 2019-nCoV into Human Cells

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment

Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Evid Based Complement Alternat Med

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Structure of RNA-dependent RNA polymerase from 2019-nCoV

Advancement in the research of mechanism of immune dysfunction in sepsis and the regulatory effects of Xuebijing injection

Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. medRxiv

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

China Medical Information Platform. National Health Commission, and National Administration of Traditional Chinese Medicine

Host and infectivity prediction of Wuhan

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses

Effects of huoxiangzhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrhea

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Triple combination of interferon beta-1b, lopinavir-ritonavir

Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease

Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19

The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus

Promotive Association for

Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review

Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells

Simultaneous determination of 13 chemical marker compounds in Gwakhyangjeonggi-san, a herbal formula, with validated analytical methods

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Antiviral activity of substituted salicylanilides--a review

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

Recent progress on the diagnosis of 2019 Novel Coronavirus

Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species

COVID-19 Disease: ORF8 and Surface Glycoprotein Inhibit Heme Metabolism by Binding to Porphyrin

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Antiinflammatory effects of Shufengjiedu capsule for upper respiratory infection via the ERK pathway

An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv

Efficacy of lianhuaqingwen granules in the management of chronic rhinosinusitis without nasal polyps

Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases. bioRxiv

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Potential covalent drugs targeting the main protease of SARS-CoV-2 coronavirus

COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients

SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv

Can Chinese Medicine Be Used for Prevention of Corona Virus Disease

A Review of Historical Classics, Research Evidence and Current Prevention Programs

Compounds with Therapeutic Potential against Novel Respiratory

Shufengjiedu capsules protect against neuronal loss in olfactory epithelium and lung injury by enhancing autophagy in rats with allergic rhinitis

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19

Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus

Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease. chemrxiv

Plausible mechanisms of Niclosamide as an antiviral against COVID-19

Guideline of the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia. National Health Commission (NHC) of the People

Antioxidant Potential of Antiviral Drug Umifenovir

Traditional Chinese medicine for COVID-19 treatment

Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. medRxiv

Effectiveness and safety of antiviral or antibody treatments for coronavirus: A rapid review. medRxiv

Mechanisms involved in the side effects of glucocorticoids

Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic

The protective effect of Xuebijing injection pretreatment on hepatic ischemia reperfusion injury and coagulopathy after excision of liver cancer

Hydroxychloroquine and covid-19

Repurposing drugs against main protease of SARS-CoV-2: mechanism based insights supported by available laboratory and clinical data. chemrxiv

Universal Screening for SARS-CoV-2 in Women Admitted for Delivery

Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship "Diamond Princess

An evaluation of Chloroquine as a broadacting antiviral against Hand, Foot and Mouth Disease

Therapeutic Mechanistic Studies of ShuFengJieDu Capsule in an Acute Lung Injury Animal Model Using Quantitative Proteomics Technology

Dexamethasone for COVID-19? Not so fast

Characteristics of COVID-19 infection in Beijing

The potential insights of Traditional Chinese Medicine on treatment of COVID-19

Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

The establishment of reference sequence for SARS-CoV-2 and variation analysis

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Elucidating the Mechanisms of Action of Chinese Medicine for the Treatment of COVID-19 via Systems Pharmacology and Virtual Screening Approaches

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Clinical benefit of remdesivir in rhesus macaques

Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

Traditional Chinese Medicine treatment of COVID-19

Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study

Chloroquine inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation

Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Theoretical Study of the anti-NCP Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (LQF). chemrxiv

The Traditional Medicine and Modern Medicine from Natural Products

Structural basis of potential binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase

The 2019 novel coronavirus resource

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Glycopeptide Antibiotics Potently

Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

This work was financially supported by the Changchun Science and Technology Bureau